WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H124974
CAS#: 2211152-69-9
Description: Lutetium Lu 177 Satoreotide Tetraxetan is a radioconjugate consisting of the somatostatin antagonistic peptide satoreotide tetraxetan (JR11).
Hodoodo Cat#: H124974
Name: Lutetium Lu 177 Satoreotide Tetraxetan
CAS#: 2211152-69-9
Chemical Formula: C74H95Cl177LuN19O21S2
Exact Mass: 1,861.55
Molecular Weight: 1,863.200
Elemental Analysis: C, 47.70; H, 5.14; Cl, 1.90; Lu, 9.50; N, 14.28; O, 18.03; S, 3.44
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Somther; CAX3X53UL6; 177Lu-DOTA-JR11; Lutetium-177 DOTA satoreotide; Lu-177 OPS-201
IUPAC/Chemical Name: lutetium(III)-177Lu 2,2',2''-(10-(2-(((S)-1-(((4R,7S,10S,13R,16S,19S)-4-(((R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamoyl)-10-(4-aminobutyl)-16-(4-((S)-2,6-dioxohexahydropyrimidine-4-carboxamido)benzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-13-(4-ureidobenzyl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl)amino)-3-(4-chlorophenyl)-1-oxopropan-2-yl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
InChi Key: LGPOVIJRCHASEQ-TWMOUGLCSA-K
InChi Code: InChI=1S/C74H98ClN19O21S2.Lu/c1-41(95)63-72(113)87-57(70(111)83-51(64(77)105)30-45-11-19-49(96)20-12-45)40-117-116-39-56(86-67(108)52(31-42-5-13-46(75)14-6-42)81-59(98)35-91-22-24-92(36-60(99)100)26-28-94(38-62(103)104)29-27-93(25-23-91)37-61(101)102)71(112)85-54(33-43-7-15-47(16-8-43)79-66(107)55-34-58(97)89-74(115)88-55)69(110)84-53(32-44-9-17-48(18-10-44)80-73(78)114)68(109)82-50(65(106)90-63)4-2-3-21-76;/h5-20,41,50-57,63,95-96H,2-4,21-40,76H2,1H3,(H2,77,105)(H,79,107)(H,81,98)(H,82,109)(H,83,111)(H,84,110)(H,85,112)(H,86,108)(H,87,113)(H,90,106)(H,99,100)(H,101,102)(H,103,104)(H3,78,80,114)(H2,88,89,97,115);/q;+3/p-3/t41-,50+,51-,52+,53-,54+,55+,56-,57+,63+;/m1./s1/i;1+2
SMILES Code: [177Lu+3].[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CC=C(NC(N)=O)C=C2)NC(=O)[C@H](CC3=CC=C(NC(=O)[C@@H]4CC(=O)NC(=O)N4)C=C3)NC(=O)[C@@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CC5=CC=C(O)C=C5)C(N)=O)NC(=O)[C@H](CC6=CC=C(Cl)C=C6)NC(=O)CN7CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC7)[C@@H](C)O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 1,863.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, Lewis JS, Raj N, Gönen M, Lohrmann C, Bodei L, Weber WA. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan. Clin Cancer Res. 2019 Dec 1;25(23):6939-6947. doi: 10.1158/1078-0432.CCR-19-1026. Epub 2019 Aug 22. PMID: 31439583; PMCID: PMC8382090.